A 2009 publication in the International Journal of Pharmaceutical Compounding (IJPC) elaborated on the formulation of a multi-component otic powder containing Amphotericin B, Chloramphenicol Palmitate, Hydrocortisone, and Sulfanilamide. The formulation yields 10 g of otic powder containing amphotericin B 470 mg, chloramphenicol palmitate 4.7 g, hydrocortisone 75 mg, sulfanilamide 4.7 g, and silica gel 55 mg. Silica gel is included as a desiccant and viscosity-enhancing excipient to help maintain a free-flowing powder. Compounding instructions consist of calculating the required quantities, accurately weighing each ingredient, triturating the powders together until a uniform mixture is obtained, and packaging the finished product in a tight, light-resistant container, with the authors noting that an accordion-style "puffer" device is suitable for administration. The instruction recommends a beyond-use date of up to 6 months, although storage conditions for the finished preparation are not otherwise specified. Recommended quality-control assessments include evaluation of overall and individual weight variation, uniformity of fill, physical appearance, color, uniformity, closure integrity, active drug assay, and physical stability (e.g., discoloration or other physical changes). The article also provides brief descriptions of the individual ingredients, including their physicochemical properties and pharmaceutical characteristics. Amphotericin B is described as a polyene antifungal antibiotic that binds ergosterol and should be protected from light during storage. Chloramphenicol palmitate, hydrocortisone, and sulfanilamide are described primarily in terms of their physical properties and topical uses. No clinical efficacy, safety, microbiologic, stability, or validation studies specific to this compounded otic powder were presented. [1]
A 2011 review on the management of chronic otitis externa advocates the use of topical therapies, including chloromycetin (chloramphenicol)-sulfanilamide-fungizone (amphotericin B)-hydrocortisone (CSF-HC) powder. The article only describes the powder as a mixture consisting of chloramphenicol 50 mg, sulfanilamide 50 mg, amphotericin B 50 mg, and hydrocortisone 1 mg. No information regarding efficacy, safety, stability, or compounding was mentioned. [2]
One of the few studies on the use of a combination otic powder for acute external otitis compared Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U) with ciprofloxacin drops and tobramycin drops in a randomized prospective trial of 120 adults (Table 1). After 3-4 days, 86% of the patients taking the Auricularum powder were cured compared to 77% of ciprofloxacin patients and 56% of tobramycin patients (p<0.05), although all patients achieved complete clinical resolution by day 14. The study evaluated a commercially manufactured powder supplied in a prepackaged multidose squeeze bottle and did not describe any compounding methods, preparation techniques, formulation procedures, stability, storage, or beyond-use dating. The authors also note that antibiotic powders such as chloramphenicol have historically been advocated because they deliver high local antibiotic concentrations without contributing moisture to the ear canal; however, there are no studies evaluating chloramphenicol powder alone or in combination with other products at the time of the publication of this review. [3]
Amphotericin deoxycholate 5 mg (typically co-formulated with chloramphenicol, sulfamethoxazole, sulfanilamide, ciprofloxacin, and/or hydrocortisone) otic capsules, administered via insufflator bulb, have been described for treatment of otitis externa or otomycosis. However, guidelines from the American Academy of Otolaryngology—Head and Neck Surgery Foundation recommend only using FDA-approved formulations for acute otitis externa; these preparations do not contain antifungals. [4], [5]
A recently published meta-analysis included 15 randomized controlled trials involving 2,309 adult patients and aimed to evaluate the efficacy and safety of commonly used topical therapies for otomycosis given the lack of standardized treatment recommendations. The meta-analysis demonstrated an overall pooled eradication rate of 73.6% across topical agents, with subgroup analyses showing wide variability in complete eradication rates ranging from 29.0% to 98.3%, largely reflecting heterogeneity in study design and treatment protocols. Adverse effects were generally mild and included otalgia, pruritus, and burning sensations. The authors concluded that topical antifungal therapy, particularly clotrimazole, remains the most commonly used and consistently effective option, although higher-quality standardized trials are still needed. Unfortunately, this analysis did not address compounded otic powder formulations or multi-drug regimens such as chloramphenicol, amphotericin B, and sulfamethoxazole. [6]